Literature DB >> 8311117

Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.

A D Snow1, R T Sekiguchi, D Nochlin, R N Kalaria, K Kimata.   

Abstract

Previous studies have shown the basement membrane form of heparan sulfate proteoglycan (HSPG) known as perlecan, co-localized to beta-amyloid protein (A beta)-containing amyloid deposits in brains of patients with Alzheimer's disease (AD) and Down's syndrome. Although HSPG was localized to diffuse A beta plaques in hippocampus, amygdala, and neocortex, it is not known whether they are present in diffuse A beta plaques in cerebellum. In the present study, Alcian blue staining and immunocytochemical techniques were used to determine whether highly sulfated glycosaminoglycans (GAGs) and/or HSPG (perlecan) were also present in diffuse A beta plaques of cerebellum. Tissues from cases of AD were examined for the co-localization of highly sulfated GAGs, HSPGs, and A beta in diffuse plaques in cerebellum in comparison with hippocampus. Consecutive serial sections of AD brain tissue were stained or immunostained with 1) the modified Bielschowsky stain; 2) a polyclonal antibody directed against synthetic A beta (1-40); 3) Congo red; 4) Alcian blue (pH 5.7) with varying concentrations of magnesium chloride for identification of sulfated and highly sulfated GAGs; and 5) polyclonal and monoclonal antibodies recognizing either the core protein or a specific GAG epitope on perlecan. All cases (7 of 7) of AD contained diffuse A beta plaques in the cerebellum as identified by positive Bielschowsky staining and A beta immunoreactivity. None of these cases demonstrated positive Alcian blue staining (at 0.3 and 0.7 mol/L MgCl2), HSPG, or HS GAG immunoreactivity in the same diffuse cerebellar plaques on adjacent serial sections. However, Alcian blue staining, HSPG, and/or HS GAG immunoreactivity were observed in blood vessel walls, choroid plexus, and within Purkinje cells, suggesting that the techniques used were reliable and specific. In cerebellum, all plaques containing amyloid cores that were Congo red-positive were also positive for highly sulfated GAGs (by Alcian blue staining at 0.7 mol/L MgCl2) and HSPG (both core protein and GAG chain) immunoreactivity. Even though HSPG immunoreactivity was not present in cerebellar diffuse plaques, all cases (4 of 4) examined demonstrated HSPG (both core protein and GAG chain) immunoreactivity in diffuse A beta plaques in hippocampus. Therefore, by Alcian blue staining and immunocytochemical methods, highly sulfated GAGs and HSPGs are not present in A beta diffuse plaques in cerebellum. Since previous studies indicate that the cerebellum contains relatively few amyloid-containing plaques in comparison with diffuse plaques, these studies suggest that HSPG may be an essential component needed for amyloid formation and/or persistence in brain as observed in cortical areas.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8311117      PMCID: PMC1887140     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Differential staining of acid glycosaminoglycans (mucopolysaccharides) by alcian blue in salt solutions.

Authors:  J E Scott; J Dorling
Journal:  Histochemie       Date:  1965-10-01

2.  Nomenclature of amyloid and amyloidosis. WHO-IUIS Nomenclature Sub-Committee.

Authors: 
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

3.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

4.  Isolation of a heparan sulfate-containing proteoglycan from basement membrane.

Authors:  J R Hassell; P G Robey; H J Barrach; J Wilczek; S I Rennard; G R Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

5.  Amyloid beta-peptide is produced by cultured cells during normal metabolism.

Authors:  C Haass; M G Schlossmacher; A Y Hung; C Vigo-Pelfrey; A Mellon; B L Ostaszewski; I Lieberburg; E H Koo; D Schenk; D B Teplow
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

6.  Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions.

Authors:  P E Fraser; J T Nguyen; D T Chin; D A Kirschner
Journal:  J Neurochem       Date:  1992-10       Impact factor: 5.372

7.  Amyloid P component and other acute-phase proteins associated with cerebellar A beta-deposits in Alzheimer's disease.

Authors:  R N Kalaria; G Perry
Journal:  Brain Res       Date:  1993-12-17       Impact factor: 3.252

8.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

9.  Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease.

Authors:  J H Su; B J Cummings; C W Cotman
Journal:  Neuroscience       Date:  1992-12       Impact factor: 3.590

10.  The amyloid P-component (protein AP): an integral part of the amyloid substance?

Authors:  M Holck; G Husby; K Sletten; J B Natvig
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

View more
  29 in total

1.  Microglia in Alzheimer's disease and transgenic models. How close the fit?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  The carbohydrate deposits detected by histochemical methods in the molecular layer of the dentate gyrus in the hippocampal formation of patients with schizophrenia, Down's syndrome and dementia, and aged person.

Authors:  A Nishimura; K Ikemoto; K Satoh; Y Yamamoto; S Rand; B Brinkmann; K Nishi
Journal:  Glycoconj J       Date:  2000-11       Impact factor: 2.916

3.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain.

Authors:  M M Verbeek; I Otte-Höller; J van den Born; L P van den Heuvel; G David; P Wesseling; R M de Waal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 4.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

Review 5.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

6.  Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells.

Authors:  Paul O'Callaghan; Elina Sandwall; Jin-Ping Li; Hong Yu; Rivka Ravid; Zhi-Zhong Guan; Toin H van Kuppevelt; Lars N G Nilsson; Martin Ingelsson; Bradley T Hyman; Hannu Kalimo; Ulf Lindahl; Lars Lannfelt; Xiao Zhang
Journal:  Brain Pathol       Date:  2008-04-11       Impact factor: 6.508

Review 7.  Extracellular matrix proteomics in schizophrenia and Alzheimer's disease.

Authors:  Manveen K Sethi; Joseph Zaia
Journal:  Anal Bioanal Chem       Date:  2016-09-06       Impact factor: 4.142

8.  Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation.

Authors:  Fang Cheng; Roberto Cappai; Giuseppe D Ciccotosto; Gabriel Svensson; Gerd Multhaup; Lars-Åke Fransson; Katrin Mani
Journal:  J Biol Chem       Date:  2011-06-03       Impact factor: 5.157

Review 9.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Heparan Sulfate and Heparin Promote Faithful Prion Replication in Vitro by Binding to Normal and Abnormal Prion Proteins in Protein Misfolding Cyclic Amplification.

Authors:  Morikazu Imamura; Naoko Tabeta; Nobuko Kato; Yuichi Matsuura; Yoshifumi Iwamaru; Takashi Yokoyama; Yuichi Murayama
Journal:  J Biol Chem       Date:  2016-11-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.